News

Revisiting Ligand Pharmaceuticals, Ready To Accumulate If Shares Dip Below $100
Ligand Pharmaceuticals offers biotech exposure with reduced risk through its royalty platform. Discover why its valuation now ...
pharmaphorum18h
MSD, Moderna cancer vaccine aces melanoma study
MSD and Moderna’s individualised cancer vaccine mRNA-4157 has shown impressive ... In the meantime, MSD (known as Merck & Co in North America) and Moderna have also started a second phase ...